Cumberland Pharmaceuticals, which sells specialty pharmaceuticals, including a new injectable treatment for pain and fever, raised $85 million by offering 5,000,000 shares at $17.00, below the expected range of $19.00 to $21.00. The Nashville, TN-based company...read more
ARYx Therapeutics, which re-engineers commercially successful drugs to eliminate safety issues, priced its 5 million share offering on Wednesday at $10. The company had revised its proposed IPO range downward to $10 from $14 to $16 earlier Wednesday morning. ...read more
Cumberland Pharmaceuticals prices IPO at $17, below the range
Cumberland Pharmaceuticals, which sells specialty pharmaceuticals, including a new injectable treatment for pain and fever, raised $85 million by offering 5,000,000 shares at $17.00, below the expected range of $19.00 to $21.00. The Nashville, TN-based company...read more
ALERT: Worst weekly perfomers: ARYx Therapeutics, Encore Bancshares, American Public Education
The following companies were the worst performing IPOs over the last five trading sessions:
...read more
ALERT: Worst weekly perfomers: ARYx Therapeutics, Whiting USA Trust I, MSCI
The following companies were the worst performing IPOs over the last five trading sessions:
...read more
Biotech ARYx Therapeutics prices at $10
ARYx Therapeutics, which re-engineers commercially successful drugs to eliminate safety issues, priced its 5 million share offering on Wednesday at $10. The company had revised its proposed IPO range downward to $10 from $14 to $16 earlier Wednesday morning. ...read more